MedTrace Logo

Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation

NCT00501241 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2009-06-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether ATI-7505 is effective in the treatment of chronic idiopathic constipation.

Conditions

  • Chronic Constipation

Interventions

DRUG

ATI-7505

Tablet,placebo, BID

DRUG

ATI-7505

ATI-7505 20 mg BID for 4 weeks

DRUG

ATI-7505

tablet, 40 mg, BID, $ weeks

DRUG

ATI-7505

80 mg ATI-7505, BID for 4 weeks

DRUG

ATI-7505

120 mg ATI-7505, BID, for 4 weeks

Sponsors & Collaborators

  • Procter and Gamble

    lead INDUSTRY

Principal Investigators

  • Tom G Todaro, MD · Procter and Gamble

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00501241 on ClinicalTrials.gov